News & Updates
Filter by Specialty:
Enzalutamide plus radium-223 improves rPFS in mCRPC
First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.
Enzalutamide plus radium-223 improves rPFS in mCRPC
12 Sep 2025
Statin exposure associated with longer OS in apalutamide-treated patients with advanced prostate cancer
A study using individual patient data from the SPARTAN and TITAN randomized clinical trials has found that statin exposure was associated with superior overall survival (OS) among all patients with advanced prostate cancer (PC) who were treated with apalutamide.
Statin exposure associated with longer OS in apalutamide-treated patients with advanced prostate cancer
28 Aug 2025
Antibiotics use after RARC lowers 90-day UTIs, complications
The use of antibiotic therapy for 30 days following robot-assisted radical cystectomy (RARC) results in reduced 90-day urinary tract infections (UTIs), infectious complications, UTI-related readmissions, and costs without an increase in adverse events (AEs), a study has shown.